[go: up one dir, main page]

FI91868B - Förfarande för framställning av terapeutiskt användbara piperazinyl-heterocykliska föreningar - Google Patents

Förfarande för framställning av terapeutiskt användbara piperazinyl-heterocykliska föreningar Download PDF

Info

Publication number
FI91868B
FI91868B FI880941A FI880941A FI91868B FI 91868 B FI91868 B FI 91868B FI 880941 A FI880941 A FI 880941A FI 880941 A FI880941 A FI 880941A FI 91868 B FI91868 B FI 91868B
Authority
FI
Finland
Prior art keywords
mmol
ethyl acetate
piperazinyl
evaporated
added
Prior art date
Application number
FI880941A
Other languages
English (en)
Finnish (fi)
Other versions
FI880941A0 (sv
FI880941A (sv
FI91868C (sv
Inventor
Iii John Adams Lowe
Arthur Adam Nagel
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22202301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI91868(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of FI880941A0 publication Critical patent/FI880941A0/sv
Publication of FI880941A publication Critical patent/FI880941A/sv
Publication of FI91868B publication Critical patent/FI91868B/sv
Application granted granted Critical
Publication of FI91868C publication Critical patent/FI91868C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)

Claims (4)

1. Förfarande för framställning av en terapeu-tiskt användbar förening med formeln 5 Ar-N^_ N- (c2h4) n-(U 10. vilken Ar är naftyl, som eventuellt är substituerad med fluor, klor, metoxi, cyan eller nitro; kinolyl; 6-hydro-xi-8-kinolyl; kinazolyl; bensoisotiazolyl; bensotiadiazo-lyl; 3-indazolyl, som eventuellt är substituerad med 1-15 trifluormetylfenyl; ftalazinyl; eller tetralinyl; n är 1 eller 2; och X och Y tillsammans med den fenyl, tili vilken de bundits, bildar en 2'-oxospiro[cyklopentan-l,3’-indoli-nyl] ; en oxindolyl, som eventuellt är substituerad med 20 1-3 C1.3-alkyl eller med en klor, fluor eller fenyl, varvid fenylen eventuellt är substituerad med en klor eller fluor; bensoxazolonyl; bensotiazolonyl; eller benso-imidazolonyl; eller för framställning av ett farmaceuti-skt godtagbart syraadditionssalt eller en hydrat därav, 25 kännetecknat därav, att ett piperazin med formeln Ar-N NH (ID 30 \-/ i vilken Ar är ovan definierad, bringas att reagera med en förening med formeln 91868 32 Hal(C2H4)n-// \—/^X i11!) 5 i vilken X, Y och n är ovan definierade och Hal är fluor, klor, brom eller jod, och, om sä önskas, förvandlas den erhällna föreningen enligt formeln I till ett farmaceu-tiskt godtagbart syraadditionssalt eller en hydrat pä ett 10 i och för sig känt sätt.
2. Förfarande enligt patentkravet 1, känne-t e c k n a t därav, att X och Y tillsammans med den fe-nyl, tili vilken de bundits, bildar bensoxazoloyl eller oxindolin. 15
3. Förfarande enligt patentkravet 1 eller 2, kännetecknat därav, att Ar är naftyl och n är 1.
4. Förfarande enligt patentkravet 1 eller 2, kännetecknat därav, att Ar är bensoisotiazo-20 lyl och n är 1. li
FI880941A 1987-03-02 1988-03-01 Förfarande för framställning av terapeutiskt användbara piperazinyl-heterocykliska föreningar FI91868C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8700423 1987-03-02
US8700423 1987-03-02

Publications (4)

Publication Number Publication Date
FI880941A0 FI880941A0 (sv) 1988-03-01
FI880941A FI880941A (sv) 1988-09-03
FI91868B true FI91868B (sv) 1994-05-13
FI91868C FI91868C (sv) 1994-08-25

Family

ID=22202301

Family Applications (1)

Application Number Title Priority Date Filing Date
FI880941A FI91868C (sv) 1987-03-02 1988-03-01 Förfarande för framställning av terapeutiskt användbara piperazinyl-heterocykliska föreningar

Country Status (31)

Country Link
EP (1) EP0281309B1 (sv)
JP (1) JPH0710837B2 (sv)
KR (1) KR900003492B1 (sv)
CN (1) CN1015057B (sv)
AR (1) AR244673A1 (sv)
AT (1) ATE70833T1 (sv)
AU (1) AU583762B2 (sv)
BA (1) BA98296A (sv)
CA (1) CA1300139C (sv)
CZ (1) CZ281257B6 (sv)
DD (1) DD272077A5 (sv)
DE (3) DE10299021I2 (sv)
DK (1) DK173065B1 (sv)
EG (1) EG18398A (sv)
ES (1) ES2040838T3 (sv)
FI (1) FI91868C (sv)
GR (1) GR3003459T3 (sv)
HU (1) HU207860B (sv)
IE (1) IE60849B1 (sv)
IL (1) IL85495A (sv)
LU (1) LU90944I2 (sv)
MX (1) MX173362B (sv)
MY (1) MY103352A (sv)
NO (2) NO170977C (sv)
NZ (1) NZ223694A (sv)
PH (1) PH24119A (sv)
PL (1) PL157897B1 (sv)
PT (1) PT86866B (sv)
SU (1) SU1644716A3 (sv)
YU (1) YU46639B (sv)
ZA (1) ZA881447B (sv)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60130573A (ja) * 1983-12-15 1985-07-12 Otsuka Pharmaceut Co Ltd ベンゾチアゾ−ル誘導体
US4720297A (en) * 1985-09-27 1988-01-19 Sumitomo Chemical Company, Limited Benzothiazolones, and their production and use as herbicides
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
FR2631625B1 (fr) * 1988-05-17 1992-10-16 Synthelabo Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique
US5015740A (en) * 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US4957916A (en) * 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
WO1990006303A1 (en) * 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
EP0429341A3 (en) * 1989-11-20 1991-11-13 Rhone-Poulenc Sante Heterocyclic derivatives, their preparation and pharmaceuticals containing them
FR2655042B1 (fr) * 1989-11-29 1994-01-21 Adir Cie Nouvelles benzothiazolinones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2655988B1 (fr) * 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5166157A (en) * 1989-12-20 1992-11-24 Adir Et Compagnie Naphthyl piperazines useful as 5-HT1A receptor ligands
US5162321A (en) * 1989-12-20 1992-11-10 Adir Et Compagnie 1-naphthyl piperazines useful as 5-HT1A receptor ligands
US5166156A (en) * 1989-12-20 1992-11-24 Adir Et Compagnie Naphthyl piperazines useful as 5-HT1A receptor ligands
US5162324A (en) * 1989-12-20 1992-11-10 Adir Et Compagnie Naphyl piperazines useful as 5-HT1A receptor ligands
FR2671350A1 (fr) * 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
US5268381A (en) * 1990-09-26 1993-12-07 Adir Et Compagnie Aminoalkyl-benzothiazolinone and -benzoxazolinone compounds having a high 5-HT1A affinity
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5147881A (en) * 1990-11-14 1992-09-15 Pfizer Inc 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
EP0635506A4 (en) * 1993-02-04 1995-04-12 Meiji Seika Co CONNECTION WITH ANTIPSYCHOTIC EFFECT.
FR2702214B1 (fr) * 1993-03-05 1995-04-14 Adir Nouveaux composés (aryl(alkyl)carbonyl)-hétérocycliques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
GB9305623D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
ES2083319B1 (es) * 1993-09-20 1997-01-16 Pfizer Monohidrato de clorhidrato de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
AU687155B2 (en) * 1994-03-22 1998-02-19 Les Laboratoires Servier Novel aminoalkyl benzothiazolinones, process for their preparation and the pharmaceutical compositions which contain them
FR2717807B1 (fr) * 1994-03-22 1996-04-19 Adir Nouvelles 6- [(4-arylalkyl-1-piperazino)alkyl] benzothiazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
US6187774B1 (en) * 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
EA001180B1 (ru) * 1996-05-07 2000-10-30 Пфайзер Инк. Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
FR2755690B1 (fr) * 1996-11-08 1998-12-18 Adir Nouveaux derives aminomethyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
JP5080716B2 (ja) 2001-07-20 2012-11-21 サイコジェニックス・インコーポレーテッド 注意欠陥・多動性障害の治療
US20060089400A1 (en) * 2002-05-03 2006-04-27 The Vernalis Group Of Companies Novel spiro ketone and carboxylic acid derivatives as specific inhibitors for (po3h2) ser/(po3h2)thr-pro-specific peptidyl-prolylcis/trans-isomerases
BR0315809A (pt) * 2002-10-28 2005-09-13 Warner Lambert Co Derivados de piperazina substituìdos com oxindol
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
WO2004100954A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
CA2525323A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
HUP0400953A3 (en) * 2004-05-11 2008-02-28 Egis Gyogyszergyar Nyilvanosan Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use
ES2317241T3 (es) * 2004-05-11 2009-04-16 Egis Gyogyszergyar Nyrt Derivados de piperazina de alquil oxindoles.
US7728136B2 (en) 2004-06-18 2010-06-01 Lupin Limited Method for the preparation of aryl piperazinyl-heterocyclic compounds
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
HUP0600868A3 (en) * 2006-11-24 2009-03-30 Richter Gedeon Nyrt 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP5431305B2 (ja) 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
WO2008128996A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
CA2729313C (en) 2008-07-03 2016-08-30 Janssen Pharmaceutica Nv Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists
EP2307374B1 (en) 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
SMT201700430T1 (it) 2009-06-25 2018-01-11 Alkermes Pharma Ireland Ltd Composti eterociclici per il trattamento di disturbi neurologici e psicologici
PL391810A1 (pl) 2010-07-14 2012-01-16 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Nowe sole ziprasidonu oraz sposoby ich otrzymywania
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
MA41169A (fr) * 2014-12-17 2017-10-24 Acraf Composés antibactériens à large spectre d'activité
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179505A (en) * 1977-03-30 1979-12-18 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
FR2536749A1 (fr) * 1982-11-25 1984-06-01 Cerm Cent Europ Rech Mauvernay (amino-2 ethyl)-6 benzoxazolinones substituees, leur preparation et leurs applications en therapeutique
US4554284A (en) * 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
JPH0625181B2 (ja) * 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
JPS6212768A (ja) * 1985-06-22 1987-01-21 サンド・アクチエンゲゼルシヤフト 新規チアゾ−ル類、その製法および医薬
MX174210B (es) * 1987-02-17 1994-04-28 Pfizer Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos

Also Published As

Publication number Publication date
NO880901D0 (no) 1988-03-01
CZ281257B6 (cs) 1996-07-17
GR3003459T3 (en) 1993-02-17
ES2040838T3 (es) 1993-11-01
CA1300139C (en) 1992-05-05
IE60849B1 (en) 1994-08-24
EP0281309B1 (en) 1991-12-27
EP0281309A1 (en) 1988-09-07
BA98296A (bs) 2001-09-14
NO880901L (no) 1988-09-05
NO2002004I2 (no) 2007-02-12
EG18398A (en) 1993-02-28
FI880941A0 (sv) 1988-03-01
HUT50330A (en) 1990-01-29
IL85495A0 (en) 1988-07-31
CZ131788A3 (en) 1996-05-15
CN1015057B (zh) 1991-12-11
NZ223694A (en) 1990-02-26
DK108388A (da) 1988-09-03
PH24119A (en) 1990-03-05
DE10299021I1 (de) 2002-09-26
ZA881447B (en) 1989-10-25
CN88101642A (zh) 1988-09-14
FI880941A (sv) 1988-09-03
HU207860B (en) 1993-06-28
DE10299021I2 (de) 2007-05-10
NO170977C (no) 1993-01-06
MX173362B (es) 1994-02-23
DD272077A5 (de) 1989-09-27
AR244673A1 (es) 1993-11-30
PT86866A (pt) 1988-03-01
LU90944I2 (fr) 2002-10-07
AU1253788A (en) 1988-09-01
JPH0710837B2 (ja) 1995-02-08
SU1644716A3 (ru) 1991-04-23
ATE70833T1 (de) 1992-01-15
FI91868C (sv) 1994-08-25
DK173065B1 (da) 1999-12-13
KR880011142A (ko) 1988-10-26
JPS63301861A (ja) 1988-12-08
PL157897B1 (pl) 1992-07-31
KR900003492B1 (ko) 1990-05-21
DE3867089D1 (de) 1992-02-06
PL270925A1 (en) 1988-12-08
PT86866B (pt) 1992-05-29
MX10621A (es) 1993-09-01
MY103352A (en) 1993-06-30
DK108388D0 (da) 1988-03-01
YU40688A (en) 1989-12-31
IL85495A (en) 1993-05-13
IE880574L (en) 1988-09-02
YU46639B (sh) 1994-01-20
AU583762B2 (en) 1989-05-04
NO170977B (no) 1992-09-28

Similar Documents

Publication Publication Date Title
FI91868B (sv) Förfarande för framställning av terapeutiskt användbara piperazinyl-heterocykliska föreningar
US4831031A (en) Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) Piperazinyl-heterocyclic compounds
DE69810889T2 (de) Heterozyklische Piperazinyl Verbindungen zur Behandlung von Demenz
JP2006528236A (ja) ジプラシドンを用いて認知を増強する方法
JPH0717633B2 (ja) ヘテロアリールピペラジン抗精神病薬
US6177569B1 (en) Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
JP2007502856A (ja) 精神病性障害および抑うつ性障害の治療
KR20060009938A (ko) 양극성 장애 및 연관된 증상의 치료
IE913940A1 (en) 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
EP0279598B1 (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
EP0204215A1 (en) 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines
JP3004969B2 (ja) トゥレット症候群の治療用薬剤
US6441175B1 (en) 1-(N'-arylalkylaminoalkyl)aminoisoquinolines: a new class of dopamine receptor subtype
KR100469188B1 (ko) 녹내장 및 허혈성 망막증 치료용 제약 조성물
HU211523A9 (hu) Neuroleptikus hatású aril-piperazinil-etil-(vagy butil)- alkilén heterociklusos vegyűletek Az átmeneti oltalom az 1-8. igénypontra vonatkozik.
Lowe et al. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
JPS61501988A (ja) ３−および５−〔ビシクリックエ−テルまたはビシクリックアルキレンチオエ−テル〕アルキレンアミノチアトリアジン類およびそれらの薬剤使用法
EP1757292A1 (en) Method of treating ocd and tic disorders

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: PFIZER INC.

MA Patent expired